HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): William A. Cooper John Parker Gott Jakob Vinten-Johansen Robert A. Guyton Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duarte, I. G. Articles by Guyton, R. A. Search for Related Content PubMed PubMed Citation Articles by Duarte, I. G. Articles by Guyton, R. A. Related Collections Valve disease Related Article

Ann Thorac Surg 2001;71:92-99
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

In vivo hemodynamic, histologic, and antimineralization characteristics of the Mosaic bioprosthesis

^a Cardiothoracic Research Laboratory, Carlyle Fraser Heart Center, Crawford Long Hospital, Emory University School of Medicine, Atlanta, Georgia, USA

Accepted for publication February 28, 2000.

Address reprint requests to Dr Brown, Division of Cardiothoracic Surgery, Crawford Long Hospital, 550 Peachtree St, Suite 7700, Atlanta, GA 30365

Background. Performance of bioprosthetic valves is limited by tissue degeneration due to calcification with reduced performance and longevity. The Mosaic bioprosthetic valve (Medtronic Heart Valves, Inc, Minneapolis, MN) combines zero pressure fixation, antimineralization properties of -amino oleic acid (AOA), and a proven stent design. We tested the hypothesis that AOA treatment of Mosaic valves improves hemodynamics, antimineralization properties, and survival in a chronic ovine model.

Methods. Mitral valves were implanted in juvenile sheep with Mosaic valves with AOA treatment (n = 8) or without AOA treatment (non-AOA, n = 8), or Hancock I (HAN, n = 4) tissue valves, and explanted at 20 postoperative weeks.

Results. Survival was equivalent in AOA and non-AOA (140 ± 0.4 and 129 ± 30 days), but was significantly less in HAN (82 ± 35). Leaflet calcium (µgCa/mg tissue) was less in AOA (9.6 ± 13.9; p < 0.05 versus non-AOA and HAN) than non-AOA (96.3 ± 63.8) and HAN (130.8 ± 43.2). Explant valve orifice area (cm²) was significantly preserved in the AOA group compared with the non-AOA group (1.5 ± 0.7 vs 0.8 ± 0.3; p < 0.05 versus non-AOA and HAN).

Conclusions. We conclude that AOA treatment of Mosaic valves reduces leaflet calcification and valve gradient in juvenile sheep, and that the Mosaic design and fixation features may offer survival advantages that must be confirmed in extended trials.

Related Article

Invited commentary

W. Gerald Rainer
Ann. Thorac. Surg. 2001 71: 99. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				F.-C. Riess, R. Bader, E. Cramer, L. Hansen, B. Kleijnen, G. Wahl, J. Wallrath, S. Winkel, and N. Bleese Hemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years Ann. Thorac. Surg., April 1, 2007; 83(4): 1310 - 1318. [Abstract] [Full Text] [PDF]

				P. A. Weber, J. Jouan, A. Matsunaga, E. Pettenazzo, T. Joudinaud, G. Thiene, and C. M.G. Duran Evidence of mitigated calcification of the Mosaic versus Hancock Standard valve xenograft in the mitral position of young sheep. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1137 - 1143. [Abstract] [Full Text] [PDF]

				M. C. Smith, F. A. Arabia, P. H. Tsau, R. G. Smith, R. K. Bose, D. S. Woolley, B. E. Rhenman, G. K. Sethi, and J. G. Copeland CardioWest Total Artificial Heart in a Moribund Adolescent With Left Ventricular Thrombi Ann. Thorac. Surg., October 1, 2005; 80(4): 1490 - 1492. [Abstract] [Full Text] [PDF]

				A. El-Banayosy, L. Arusoglu, M. Morshuis, L. Kizner, G. Tenderich, P. Sarnowski, H. Milting, and R. Koerfer CardioWest Total Artificial Heart: Bad Oeynhausen Experience Ann. Thorac. Surg., August 1, 2005; 80(2): 548 - 552. [Abstract] [Full Text] [PDF]

				J. G. Copeland, R. G. Smith, F. A. Arabia, P. E. Nolan, G. K. Sethi, P. H. Tsau, D. McClellan, M. J. Slepian, and the CardioWest Total Artificial Heart Investigator Cardiac Replacement with a Total Artificial Heart as a Bridge to Transplantation N. Engl. J. Med., August 26, 2004; 351(9): 859 - 867. [Abstract] [Full Text] [PDF]

				R. Seitelberger, J. Bialy, R. Gottardi, G. Seebacher, R. Moidl, M. Mittelbock, P. Simon, and E. Wolner Relation between size of prosthesis and valve gradient: comparison of two aortic bioprosthesis Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 358 - 363. [Abstract] [Full Text] [PDF]

				O. H. Frazier, N. A. Shah, and T. J. Myers Total Artificial Heart Card. Surg. Adult, January 1, 2003; 2(2003): 1507 - 1514. [Full Text]

				F. W. H. Sutherland and J. E. Mayer Jr. Tissue engineering for cardiac surgery Card. Surg. Adult, January 1, 2003; 2(2003): 1527 - 1536. [Full Text]

				A. Sezai, L. Arusoglu, K. Minami, A. El-Banayosy, and R. Korfer Implantation of biventricular assist devices for chronic heart transplant rejection Ann. Thorac. Surg., August 1, 2002; 74(2): 609 - 611. [Abstract] [Full Text] [PDF]

				W. B. Eichinger, F. Botzenhardt, R. Gunzinger, B. M. Kemkes, A. Sosnowski, D. Maiza, E. O. Coto, and N. Bleese European experience with the Mosaic bioprosthesis J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 333 - 339. [Abstract] [Full Text] [PDF]